Oligomerix
Dr. Cheesman is a pharmaceutical PHO chemist with over 20 years of leadership experience in the discovery and development of pharmaceuticals from preclinical through commercial launch, with demonstrated success in on-time delivery of clinical supply and cost-driven process optimization. He recently joined Oligomerix in a part-time role managing all matters related to chemistry. Since 2014, he has been the Principal Consultant at EHC Solutions and Principal Chemistry Consultant for Impact Technology Development, working with small pharmacy and startups in chemical development, assisting in lead development, technology transfer, and management of small molecule process development projects at CDMOs. Prior to that, he was Director of Chemical Development at Lathes Medical Imaging and formerly Principal Investigator/Sir Principal Investigator, Discovery and Process Chemistry at Bristol-Myers Squibb Medical Imaging. He is also an inventor with 15 issued US patents.
This person is not in any offices
Oligomerix
Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for Alzheimer’s disease and related dementias by targeting tau self-association. The company’s drug discovery platform has identified a pipeline of novel small molecule inhibitors, with preclinical IND-enabling studies in progress for the lead program. Oligomerix’s small molecule approach blocks the formation of all tau aggregates by targeting tau self-association, known as the beginning of the aggregation cascade, whereas other companies have focused on targeting large tau aggregates formed downstream. The NYC-based company is located at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.